Bausch Health Companies (NYSE:BHC) Stock Rating Upgraded by StockNews.com

Bausch Health Companies (NYSE:BHC) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other research analysts also recently issued reports on BHC. Piper Sandler downgraded shares of Bausch Health Companies from a “neutral” rating to an “underweight” rating and decreased their price target for the stock from $9.00 to $3.00 in a research note on Friday, August 2nd. Jefferies Financial Group decreased their price target on shares of Bausch Health Companies from $13.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, August 7th. Scotiabank decreased their price target on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research note on Friday, August 2nd. Royal Bank of Canada decreased their price target on shares of Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating for the company in a research note on Friday, August 2nd. Finally, Raymond James started coverage on shares of Bausch Health Companies in a research note on Wednesday, July 10th. They issued a “market perform” rating and a $8.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $7.33.

Bausch Health Companies Stock Performance

Shares of BHC stock opened at $6.21 on Friday. The stock has a market capitalization of $2.24 billion, a P/E ratio of -5.01 and a beta of 0.77. The company has a 50 day moving average price of $6.33 and a 200 day moving average price of $7.50. Bausch Health Companies has a fifty-two week low of $3.96 and a fifty-two week high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.33 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. During the same quarter in the previous year, the business posted $0.81 earnings per share. On average, research analysts forecast that Bausch Health Companies will post 3.61 EPS for the current fiscal year.

Institutional Trading of Bausch Health Companies

Institutional investors have recently modified their holdings of the stock. Salem Investment Counselors Inc. purchased a new stake in Bausch Health Companies in the 1st quarter valued at $32,000. Principal Securities Inc. purchased a new stake in Bausch Health Companies in the 4th quarter valued at $31,000. Headlands Technologies LLC purchased a new stake in Bausch Health Companies in the 2nd quarter valued at $35,000. MQS Management LLC purchased a new stake in Bausch Health Companies in the 2nd quarter valued at $71,000. Finally, Certuity LLC purchased a new stake in Bausch Health Companies in the 2nd quarter valued at $75,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.